The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer

Malgorzata Banys-Paluchowski; Isabell Witzel; Sabine Riethdorf; Klaus Pantel; Brigitte Rack; Wolfgang Janni; Peter A. Fasching; Bahriye Aktas; Sabine Kasimir-Bauer; Andreas Hartkopf; Erich Franz Solomayer; Tanja Fehm; Volkmar Müller

doi:10.1007/s10549-018-4882-z

The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer

Malgorzata Banys-Paluchowski, Isabell Witzel, Sabine Riethdorf, Klaus Pantel, Brigitte Rack, Wolfgang Janni, Peter A. Fasching, Bahriye Aktas, Sabine Kasimir-Bauer, Andreas Hartkopf, Erich Franz Solomayer, Tanja Fehm, Volkmar Müller^*

^*Korrespondierende/r Autor/-in für diese Arbeit

Klinik für Frauenheilkunde und Geburtshilfe

35 Zitate (Scopus)

Abstract

Purpose: VEGF is one of the most important angiogenesis-stimulating cytokines and has been previously shown to be overexpressed in several solid cancers. The aim of the present study was to assess the clinical relevance of serum VEGF (sVEGF) in a large cohort of metastatic breast cancer patients and to explore the relationship between sVEGF and other blood-based biomarkers. Methods: Two hundred fifty-three patients with metastatic breast cancer were enrolled in this prospective, multicentre study. Blood samples were collected before start of first-line or later-line treatment. sVEGF was quantified by a commercially available ELISA. Circulating tumor cells (CTCs) were detected using CellSearch and other biomarkers (EGFR, HER2, RAS p21, TIMP1, CAIX) by ELISA. Results: Levels of sVEGF were determined in all patients, with a median concentration of 231 pg/ml. After a median follow-up of 19 months, median overall survival (OS) was 10.2 months in patients with sVEGF levels above the upper quartile (i.e. 367 pg/ml), while median OS has not been reached in patients with sVEGF < 367 pg/ml (p < 0.001). Median progression-free survival (PFS) was 4.8 months for patients with sVEGF ≥ 367 pg/ml versus 9.1 months with sVEGF levels < 367 pg/ml (p < 0.001). Patients with sVEGF levels ≥ 367 pg/ml and ≥ 5 CTCs had the shortest OS, while those with sVEGF < 367 pg/ml and non-elevated CTCs had the longest OS. CTCs, grading, line of therapy and RAS p21 were independent predictors of OS. sVEGF, line of therapy and CTCs were independent predictors of PFS in the multivariate analysis. Conclusions: Metastatic breast cancer patients with elevated levels of sVEGF have significantly worse clinical outcome. This finding supports the biological role of VEGF in breast cancer. Trial registration: Current Controlled Trials ISRCTN59722891 (DETECT).

Originalsprache	Englisch
Zeitschrift	Breast Cancer Research and Treatment
Jahrgang	172
Ausgabenummer	1
Seiten (von - bis)	93-104
Seitenumfang	12
ISSN	0167-6806
DOIs	https://doi.org/10.1007/s10549-018-4882-z
Publikationsstatus	Veröffentlicht - 01.11.2018

Fördermittel

Funding The DETECT study was supported by a research grant from Roche Pharma AG, Germany and by Adnagen AG, Germany. ELISA kits were provided at no cost by Oncogene Science. The funding agencies had no role in study design or collection, analysis and interpretation of data or in the writing of the manuscript. Conflict of interest Wolfgang Janni received a research grant from Roche. Bahriye Aktas has served as a consultant/advisor for Roche, Pfizer and Novartis. Klaus Pantel has served as a consultant/advisor for Agena Bioscience. Sabine Kasimir-Bauer has served as a consultant/ advisor for Qiagen. Peter A. Fasching has served as a consultant/advisor for Amgen, Novartis, Roche, Pfizer, Teva and Puma Celgene and received a research grant from Novartis. Brigitte Rack has received honoraria or research grants from Novartis, Roche, Pfizer, Janssen Diagnostics, Astra Zeneca, Novartis, Lilly, Chugai and Sanofi. Mal-gorzata Banys-Paluchowski, Isabell Witzel, Sabine Riethdorf, Andreas Hartkopf, Erich-Franz Solomayer, Tanja Fehm and Volkmar Müller declare that they have no conflicts of interest. This study was conducted on behalf of the DETECT Study Group. Wolfgang Janni received a research grant from Roche. Bahriye Aktas has served as a consultant/advisor for Roche, Pfizer and Novartis. Klaus Pantel has served as a consultant/advisor for Agena Bioscience. Sabine Kasimir-Bauer has served as a consultant/advisor for Qiagen. Peter A. Fasching has served as a consultant/advisor for Amgen, Novartis, Roche, Pfizer, Teva and Puma Celgene and received a research grant from Novartis. Brigitte Rack has received honoraria or research grants from Novartis, Roche, Pfizer, Janssen Diagnostics, Astra Zeneca, Novartis, Lilly, Chugai and Sanofi. Malgorzata Banys-Paluchowski, Isabell Witzel, Sabine Riethdorf, Andreas Hartkopf, Erich-Franz Solomayer, Tanja Fehm and Volkmar M?ller declare that they have no conflicts of interest.

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

Dokumente

10.1007/s10549-018-4882-z

Weitere Links

Link to publication in Scopus

Fingerprint

Untersuchen Sie die Forschungsthemen von „The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren

Banys-Paluchowski, M., Witzel, I., Riethdorf, S., Pantel, K., Rack, B., Janni, W., Fasching, P. A., Aktas, B., Kasimir-Bauer, S., Hartkopf, A., Solomayer, E. F., Fehm, T., & Müller, V. (2018). The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer. Breast Cancer Research and Treatment, 172(1), 93-104. https://doi.org/10.1007/s10549-018-4882-z

@article{dab8fbcceecb4eb19f7d342758a41c30,

title = "The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer",

abstract = "Purpose: VEGF is one of the most important angiogenesis-stimulating cytokines and has been previously shown to be overexpressed in several solid cancers. The aim of the present study was to assess the clinical relevance of serum VEGF (sVEGF) in a large cohort of metastatic breast cancer patients and to explore the relationship between sVEGF and other blood-based biomarkers. Methods: Two hundred fifty-three patients with metastatic breast cancer were enrolled in this prospective, multicentre study. Blood samples were collected before start of first-line or later-line treatment. sVEGF was quantified by a commercially available ELISA. Circulating tumor cells (CTCs) were detected using CellSearch and other biomarkers (EGFR, HER2, RAS p21, TIMP1, CAIX) by ELISA. Results: Levels of sVEGF were determined in all patients, with a median concentration of 231 pg/ml. After a median follow-up of 19 months, median overall survival (OS) was 10.2 months in patients with sVEGF levels above the upper quartile (i.e. 367 pg/ml), while median OS has not been reached in patients with sVEGF < 367 pg/ml (p < 0.001). Median progression-free survival (PFS) was 4.8 months for patients with sVEGF ≥ 367 pg/ml versus 9.1 months with sVEGF levels < 367 pg/ml (p < 0.001). Patients with sVEGF levels ≥ 367 pg/ml and ≥ 5 CTCs had the shortest OS, while those with sVEGF < 367 pg/ml and non-elevated CTCs had the longest OS. CTCs, grading, line of therapy and RAS p21 were independent predictors of OS. sVEGF, line of therapy and CTCs were independent predictors of PFS in the multivariate analysis. Conclusions: Metastatic breast cancer patients with elevated levels of sVEGF have significantly worse clinical outcome. This finding supports the biological role of VEGF in breast cancer. Trial registration: Current Controlled Trials ISRCTN59722891 (DETECT).",

author = "Malgorzata Banys-Paluchowski and Isabell Witzel and Sabine Riethdorf and Klaus Pantel and Brigitte Rack and Wolfgang Janni and Fasching, \{Peter A.\} and Bahriye Aktas and Sabine Kasimir-Bauer and Andreas Hartkopf and Solomayer, \{Erich Franz\} and Tanja Fehm and Volkmar M{\"u}ller",

note = "Publisher Copyright: {\textcopyright} 2018, Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2018",

month = nov,

day = "1",

doi = "10.1007/s10549-018-4882-z",

language = "English",

volume = "172",

pages = "93--104",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer",

number = "1",

}

Banys-Paluchowski, M, Witzel, I, Riethdorf, S, Pantel, K, Rack, B, Janni, W, Fasching, PA, Aktas, B, Kasimir-Bauer, S, Hartkopf, A, Solomayer, EF, Fehm, T & Müller, V 2018, 'The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer', Breast Cancer Research and Treatment, Jg. 172, Nr. 1, S. 93-104. https://doi.org/10.1007/s10549-018-4882-z

The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer. / Banys-Paluchowski, Malgorzata; Witzel, Isabell; Riethdorf, Sabine et al.
in: Breast Cancer Research and Treatment, Jahrgang 172, Nr. 1, 01.11.2018, S. 93-104.

Publikation: Beiträge in Fachzeitschriften › Zeitschriftenaufsätze › Forschung › Begutachtung

TY - JOUR

T1 - The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer

AU - Banys-Paluchowski, Malgorzata

AU - Witzel, Isabell

AU - Riethdorf, Sabine

AU - Pantel, Klaus

AU - Rack, Brigitte

AU - Janni, Wolfgang

AU - Fasching, Peter A.

AU - Aktas, Bahriye

AU - Kasimir-Bauer, Sabine

AU - Hartkopf, Andreas

AU - Solomayer, Erich Franz

AU - Fehm, Tanja

AU - Müller, Volkmar

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Purpose: VEGF is one of the most important angiogenesis-stimulating cytokines and has been previously shown to be overexpressed in several solid cancers. The aim of the present study was to assess the clinical relevance of serum VEGF (sVEGF) in a large cohort of metastatic breast cancer patients and to explore the relationship between sVEGF and other blood-based biomarkers. Methods: Two hundred fifty-three patients with metastatic breast cancer were enrolled in this prospective, multicentre study. Blood samples were collected before start of first-line or later-line treatment. sVEGF was quantified by a commercially available ELISA. Circulating tumor cells (CTCs) were detected using CellSearch and other biomarkers (EGFR, HER2, RAS p21, TIMP1, CAIX) by ELISA. Results: Levels of sVEGF were determined in all patients, with a median concentration of 231 pg/ml. After a median follow-up of 19 months, median overall survival (OS) was 10.2 months in patients with sVEGF levels above the upper quartile (i.e. 367 pg/ml), while median OS has not been reached in patients with sVEGF < 367 pg/ml (p < 0.001). Median progression-free survival (PFS) was 4.8 months for patients with sVEGF ≥ 367 pg/ml versus 9.1 months with sVEGF levels < 367 pg/ml (p < 0.001). Patients with sVEGF levels ≥ 367 pg/ml and ≥ 5 CTCs had the shortest OS, while those with sVEGF < 367 pg/ml and non-elevated CTCs had the longest OS. CTCs, grading, line of therapy and RAS p21 were independent predictors of OS. sVEGF, line of therapy and CTCs were independent predictors of PFS in the multivariate analysis. Conclusions: Metastatic breast cancer patients with elevated levels of sVEGF have significantly worse clinical outcome. This finding supports the biological role of VEGF in breast cancer. Trial registration: Current Controlled Trials ISRCTN59722891 (DETECT).

AB - Purpose: VEGF is one of the most important angiogenesis-stimulating cytokines and has been previously shown to be overexpressed in several solid cancers. The aim of the present study was to assess the clinical relevance of serum VEGF (sVEGF) in a large cohort of metastatic breast cancer patients and to explore the relationship between sVEGF and other blood-based biomarkers. Methods: Two hundred fifty-three patients with metastatic breast cancer were enrolled in this prospective, multicentre study. Blood samples were collected before start of first-line or later-line treatment. sVEGF was quantified by a commercially available ELISA. Circulating tumor cells (CTCs) were detected using CellSearch and other biomarkers (EGFR, HER2, RAS p21, TIMP1, CAIX) by ELISA. Results: Levels of sVEGF were determined in all patients, with a median concentration of 231 pg/ml. After a median follow-up of 19 months, median overall survival (OS) was 10.2 months in patients with sVEGF levels above the upper quartile (i.e. 367 pg/ml), while median OS has not been reached in patients with sVEGF < 367 pg/ml (p < 0.001). Median progression-free survival (PFS) was 4.8 months for patients with sVEGF ≥ 367 pg/ml versus 9.1 months with sVEGF levels < 367 pg/ml (p < 0.001). Patients with sVEGF levels ≥ 367 pg/ml and ≥ 5 CTCs had the shortest OS, while those with sVEGF < 367 pg/ml and non-elevated CTCs had the longest OS. CTCs, grading, line of therapy and RAS p21 were independent predictors of OS. sVEGF, line of therapy and CTCs were independent predictors of PFS in the multivariate analysis. Conclusions: Metastatic breast cancer patients with elevated levels of sVEGF have significantly worse clinical outcome. This finding supports the biological role of VEGF in breast cancer. Trial registration: Current Controlled Trials ISRCTN59722891 (DETECT).

UR - https://www.scopus.com/pages/publications/85049795739

U2 - 10.1007/s10549-018-4882-z

DO - 10.1007/s10549-018-4882-z

M3 - Journal articles

C2 - 30003393

AN - SCOPUS:85049795739

SN - 0167-6806

VL - 172

SP - 93

EP - 104

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 1

ER -